造血干/祖细胞基因治疗Hurler综合征后的早期骨骼结局
8例MPSIH患者(治疗时平均年龄1.9岁)在1/2期临床试验(NCT03488394)中接受慢病毒HSPC-GT,评估骨骼发育不良指标至治疗后4年,并与HSCT外部队列回顾性比较。中位随访3.78年时,HSPC-GT组纵向生长位于WHO参考范围内,中位身高增幅大于HSCT组3年随访;关节活动度完全且更早正常化;髋臼指数和迁移百分比进行性下降,脊柱MRI评分稳定。临床、功能和影像学指标提示HSPC-GT对MPSIH典型骨骼特征有早期有益效应,需更长随访才能得出明确结论。
要点
- HSPC-GT后中位随访3.78年,患者纵向生长位于WHO参考范围,中位身高增幅大于HSCT组3年随访。
- HSPC-GT组关节活动度完全且更早正常化,髋臼指数和迁移百分比进行性下降。
- 脊柱MRI评分在HSPC-GT后稳定,临床、功能和影像学指标提示早期有益效应。
核心结论
- 临床、功能和影像学指标提示HSPC-GT对MPSIH典型骨骼特征有早期有益效应,但需更长随访才能对HSPC-GT影响MPSIH骨骼发育不良得出明确结论。
研究设计与样本
- 1/2期临床试验(NCT03488394)纳入8例MPSIH患者,治疗时平均年龄1.9岁,接受慢病毒HSPC-GT。
- 在基线和治疗后至4年的多个时间点评估骨骼发育不良的临床、功能和影像学指标。
- 特定骨骼指标与HSCT治疗的外部队列进行回顾性比较。
主要发现
- HSPC-GT后中位随访3.78年,所有患者纵向生长位于WHO参考范围内,中位身高增幅大于HSCT组3年随访。
- HSPC-GT组关节活动度完全且更早正常化,髋臼指数和迁移百分比进行性下降,提示髋臼发育不良减轻。
- 脊柱MRI评分显示的典型脊柱改变在HSPC-GT后稳定。
关键数值与推荐
- 髋臼指数和迁移百分比在HSPC-GT后进行性下降。
- 脊柱MRI评分在HSPC-GT后稳定。
- 中位随访3.78年时,HSPC-GT组纵向生长位于WHO参考范围内。
局限性
- 原文结论指出需更长随访才能对HSPC-GT影响MPSIH骨骼发育不良得出明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mucopolysaccharidosis type I Hurler (MPSIH) is characterized by severe and progressive skeletal dysplasia that is not fully addressed by allogeneic hematopoietic stem cell transplantation (HSCT). Autologous hematopoietic stem progenitor cell-gene therapy (HSPC-GT) provides superior metabolic correction in patients with MPSIH compared with HSCT; however, its ability to affect skeletal manifestations is unknown. Eight patients with MPSIH (mean age at treatment: 1.9 years) received lentiviral-based HSPC-GT in a phase 1/2 clinical trial (NCT03488394). Clinical (growth, measures of kyphosis and genu velgum), functional (motor function, joint range of motion), and radiological [acetabular index (AI), migration percentage (MP) in hip x-rays and MRIs and spine MRI score] parameters of skeletal dysplasia were evaluated at baseline and multiple time points up to 4 years after treatment. Specific skeletal measures were retrospectively compared with an external cohort of HSCT-treated patients. At a median follow-up of 3.78 years after HSPC-GT, all patients treated with HSPC-GT exhibited longitudinal growth within WHO reference ranges and a median height gain greater than that observed in patients treated with HSCT after 3-year follow-up. Patients receiving HSPC-GT experienced complete and earlier normalization of joint mobility compared with patients treated with HSCT. Mean AI and MP showed progressive decreases after HSPC-GT, suggesting a reduction in acetabular dysplasia. Typical spine alterations measured through a spine MRI score stabilized after HSPC-GT. Clinical, functional, and radiological measures suggested an early beneficial effect of HSPC-GT on MPSIH-typical skeletal features. Longer follow-up is needed to draw definitive conclusions on HSPC-GT's impact on MPSIH skeletal dysplasia.
引用
- Consiglieri G, Tucci F, De Pellegrin M, et al. Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome. Sci Transl Med. 2024. PMID: 38691622. doi:10.1126/scitranslmed.adi8214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。